What is the market price of Vandetanib?

Vandetanib is an oral multi-target tyrosine kinase inhibitor mainly used to treat patients with advanced or metastatic medullary thyroid cancer (MTC; thyroid cancer), especially those who cannot be cured by surgery. Its mechanism of action is to inhibit tumor angiogenesis and tumor cell proliferation by blocking specific tyrosine kinase signaling pathways, including vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and RET proto-oncogene, thereby slowing down tumor progression. As a targeted drug, vandetanib can provide personalized treatment options for patients with specific genetic mutations or high-risk patients. Compared with traditional chemotherapy, it causes less damage to healthy cells and is relatively better tolerated.

Currently, vandetanib has not been officially launched in China, so the domestic market price and relevant medical insurance policies are still unknown. In overseas markets, the common specifications of vandetanib are300mg × 30 tablets, and the price per box is about 45,000 yuan. Since there are currently no official generic drugs on the market, patients need to obtain them through formal channels when purchasing overseas, and the cost is relatively high. Some overseas markets offer pharmaceutical assistance programs or insurance coverage, and consultation with the local medical system can be based on patient needs. In addition, the use of vandetanib must be conducted under the guidance of a professional physician to ensure safety, effectiveness and compliance with individualized treatment plans.

The clinical application of vandetanib is not limited to advanced medullary thyroid cancer, but is also being studied in some early-stage or high-risk patients with RET mutations to delay disease progression or reduce the risk of surgical recurrence. This has gradually increased the strategic position of vandetanib in the treatment of thyroid cancer, especially for patient groups with clear molecular targets, providing new hope for patients with insufficient traditional treatment methods or limited surgery. In clinical use, doctors usually combine the patient's genetic test results, tumor burden, and overall health status to formulate the optimal dosage plan.

Reference materials:https://www.drugs.com/caprelsa.html